Biofrontera Inc. Earnings Per Share Disclosure

19. Net Loss per Share

 

Basic net loss per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is calculated by dividing net loss by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of stock-based awards based on the treasury stock method. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive.

 

The following table sets forth the computation of the Company’s basic and diluted net earnings (loss) per share attributable to common stockholders (in thousands, except share and per share data):

 

 Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders

		2025				2024
		For years ended December 31,
		2025				2024
Net loss		$	(10,536	)		$	(17,759	)
Weighted average common shares outstanding, basic and diluted			10,171,921				5,516,334
Net loss per share, basic and diluted		$	(1.04	)		$	(3.22	)

 

 

The following table sets forth securities that were anti-dilutive for diluted earnings per share (“EPS”) for the periods presented but which could potentially dilute EPS in the future:

 

 Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share

December 31,		2025				2024
Common stock warrants			2,269,356				2,269,356
Common stock options and RSUs			2,299,218				1,808,718
Unit Purchase Options			20,182				20,182
Series B-2 convertible preferred stock			2,896,650				14,318,632
Series B-3 convertible preferred stock			9,315,909				-
Series C convertible preferred stock			17,153,187				-
Series D convertible preferred stock			4,831,185				-
Convertible notes			6,006,345				5,384,615
Total			44,792,032				23,801,503
Anti-dilutive securities			44,792,032				23,801,503